H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Electrocore (ECOR – Research Report) today and set a price target of $7.00. The company’s shares opened today at $3.65.
According to TipRanks, Ramakanth is an analyst with an average return of -16.5% and a 27.66% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Asensus Surgical, Corcept Therapeutics, and ImmunoGen.
Electrocore has an analyst consensus of Moderate Buy, with a price target consensus of $12.88.
See the top stocks recommended by analysts >>
ECOR market cap is currently $16.23M and has a P/E ratio of -0.81.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ECOR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache. The company was founded by Joseph P. Errico, Steve Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Morris Plains, NJ.
Read More on ECOR:
- electroCore Announces Fourth Quarter and Full Year 2022 Financial Results
- electroCore regains compliance with Nasdaq listing requirements
- electroCore announces exclusive distribution agreement with Byond Healthcare
- electroCore expands intellectual patent portfolio with nVNS technology
- electroCore completes sale of New Jersey tax benefits
